TECX
Tectonic Therapeutic, Inc. NASDAQ Listed Jun 21, 2018$30.98
After hrs
$30.98
+0.00%
Mkt Cap $567.6M
52w Low $14.71
70.1% of range
52w High $37.93
50d MA $31.10
200d MA $25.74
P/E (TTM)
-6.8x
EV/EBITDA
—
P/B
2.3x
Debt/Equity
0.0x
ROE
-29.5%
P/FCF
-9.4x
RSI (14)
44.20
ATR (14)
$1.41
Beta
1.33
50d MA
$31.10
200d MA
$25.74
Avg Volume
202.1K
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
490 Arsenal Way · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -1.35 | -1.18 | +12.5% | 30.22 | +1.9% | +2.5% | — | — | — | — | — |
| May 7, 2026 | AMC | -1.16 | -1.34 | -15.5% | 26.87 | +0.5% | +7.9% | -5.1% | +1.6% | +3.0% | +3.4% | — |
| Feb 26, 2026 | AMC | -1.11 | -1.03 | +7.2% | 23.93 | +0.8% | -2.0% | -1.9% | +6.1% | +12.3% | +1.6% | — |
| Nov 6, 2025 | AMC | -1.05 | -1.02 | +2.9% | 18.99 | -2.0% | +1.7% | -2.3% | +0.5% | -0.6% | -6.8% | — |
| Aug 7, 2025 | AMC | -0.98 | -1.07 | -9.2% | 21.92 | -4.2% | +1.8% | -0.9% | -1.0% | +1.0% | +10.8% | — |
| May 8, 2025 | AMC | -1.10 | -0.93 | +15.5% | 21.02 | +0.8% | -6.0% | +4.8% | -2.5% | -1.4% | +4.0% | — |
| Mar 20, 2025 | AMC | -1.39 | -0.84 | +39.6% | 22.18 | +4.0% | -4.6% | +1.2% | -0.8% | -10.4% | -0.5% | — |
| Nov 7, 2024 | AMC | -0.84 | -1.20 | -42.9% | 45.33 | -3.2% | -3.0% | +4.8% | +3.6% | -2.1% | -7.4% | — |
| Aug 14, 2024 | AMC | -1.96 | -3.81 | -94.4% | 16.06 | +1.5% | +5.2% | +0.7% | -1.0% | -0.9% | -2.6% | — |
| May 9, 2024 | AMC | -4.32 | -1.80 | +58.3% | 15.00 | +0.0% | -1.6% | +9.8% | -4.4% | +6.2% | +1.5% | — |
| Mar 14, 2024 | AMC | -4.04 | -2.40 | +40.6% | 15.24 | -1.6% | +2.4% | -0.8% | -2.3% | +1.6% | -2.3% | — |
| Nov 9, 2023 | AMC | -4.22 | -5.76 | -36.4% | 17.88 | -5.4% | -8.1% | -3.6% | +0.0% | +1.5% | -6.0% | — |
| Sep 29, 2023 | AMC | -4.22 | -5.81 | -37.7% | 18.48 | +0.0% | -0.6% | -2.6% | -1.3% | +3.4% | +3.9% | — |
| Jun 29, 2023 | AMC | -6.49 | 18.29 | +381.8% | 10.80 | +1.1% | +5.6% | +3.2% | +2.0% | -2.0% | +1.0% | — |
| Mar 30, 2023 | AMC | -6.45 | -6.80 | -5.5% | 11.28 | +1.1% | +6.4% | -2.0% | -4.1% | -4.3% | +7.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 26 | Raymond James | Upgrade | Outperform → Strong Buy | $81 | $29.12 | $30.92 | +6.2% | +3.0% | +1.5% | -2.1% | +4.7% | -7.3% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $21.74 | $21.26 | -2.2% | -1.3% | -4.2% | -4.7% | +0.8% | -0.4% |
| May 15 | Mizuho | Maintains | Outperform → Outperform | — | $19.90 | $20.22 | +1.6% | +4.0% | +1.4% | +11.5% | +4.9% | -8.1% |
| Mar 21 | Wells Fargo | Maintains | Overweight → Overweight | — | $22.18 | $23.06 | +4.0% | -4.6% | +1.2% | -0.8% | -10.4% | -0.5% |
| Jan 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $54.84 | $54.99 | +0.3% | -1.3% | -6.5% | -5.1% | -2.5% | -9.0% |
| Nov 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $46.07 | $47.99 | +4.2% | +3.6% | -2.1% | -7.4% | -6.5% | -3.9% |
| Nov 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $43.96 | $44.13 | +0.4% | +4.8% | +3.6% | -2.1% | -7.4% | -6.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | McNamara Peter | Chief Scientific Officer | Sell | 172 | $35.00 | $6K | 55,285 | +15.85% | -0.59% |
| May 4, 2026 | Ruddy Marcella K. | Chief Medical Officer | Sell | 1,065 | $30.00 | $32K | 67,682 | -7.41% | +3.04% |
8-K · 8.01
!! High
Tectonic Therapeutic, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 10
8-K · 2.02
!! High
Tectonic Therapeutic, Inc. -- 8-K 2.02: Earnings Results
Tectonic Therapeutic reported Q1 2026 financial results and business updates, providing investors visibility into operational performance and strategic progress during the quarter.
May 7
8-K · 7.01
! Medium
Tectonic Therapeutic, Inc. -- 8-K 7.01: Regulation FD Disclosure
Tectonic Therapeutic (TECX) strengthened its board governance by appointing Ms. Chutter as a director and Audit Committee member, enhancing oversight capabilities.
Apr 23
8-K
Tectonic Therapeutic, Inc. -- 8-K Filing
Tectonic Therapeutic reported positive Phase 1b results for TX45 in pulmonary hypertension treatment, advancing its clinical pipeline and potentially validating its therapeutic approach for heart failure patients.
Feb 26
8-K · 7.01
! Medium
Tectonic Therapeutic, Inc. -- 8-K 7.01: Regulation FD Disclosure
Tectonic Therapeutic appointed Dr. Nader as Board Chair, signaling leadership restructuring that may influence the company's strategic direction and governance.
Feb 24
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Sensei Biotherapeutics appointed a new CFO with significant biotech finance experience, including prior roles at Jaguar Gene Therapy and board positions at Tectonic Therapeutic, strengthening leadership capabilities.
Feb 13
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 2,816,494 | $87M | — | Mar 2026 |
| 2 | Braidwell Lp | 927,524 | $19M | Added | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 473,532 | $15M | New | Mar 2026 |
| 4 | Bollard Group Llc | 302,953 | $9M | — | Mar 2026 |
| 5 | Marshall Wace, Llp | 229,595 | $7M | Added | Mar 2026 |
| 6 | Opaleye Management Inc. | 214,747 | $4M | New | Dec 2025 |
| 7 | Morgan Stanley | 188,870 | $4M | Reduced | Dec 2025 |
| 8 | Soleus Capital Management, L.p. | 121,684 | $4M | New | Mar 2026 |
| 9 | D.e. Shaw & Co | 116,120 | $4M | Reduced | Mar 2026 |
| 10 | Wells Fargo & Company/mn | 112,664 | $3M | New | Mar 2026 |
| 11 | Woodline Partners Lp | 100,000 | $3M | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 78,353 | $2M | Added | Mar 2026 |
| 13 | Point72 Asset Management | 68,598 | $2M | Reduced | Mar 2026 |
| 14 | Raymond James Financial Inc | 64,196 | $2M | Added | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 63,607 | $2M | New | Mar 2026 |
| 16 | Millennium Management | 58,348 | $2M | Reduced | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 58,870 | $2M | Added | Mar 2026 |
| 18 | Connor, Clark & Lunn Investment Management Ltd. | 71,657 | $1M | Added | Dec 2025 |
| 19 | Sei Investments Co | 36,870 | $1M | Added | Mar 2026 |
| 20 | Ubs Group Ag | 29,987 | $927K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$567.6M
Enterprise Value
$313.9M
P/E (TTM)
-6.78x
Forward P/E
—
PEG Ratio
-1.69x
P/B
2.26x
P/S
—
P/FCF
-9.42x
EV/EBITDA
—
Shares Out
18.3M
Financials (TTM)
Revenue
$0
Net Income
-$85.8M
EBITDA
-$83.8M
Free Cash Flow
-$60.3M
Op Cash Flow
-$60.1M
EPS Basic
$-4.05
EPS Diluted
$-4.57
EPS Forward
$-4.88
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$261.0M
Total Liab.
$9.7M
Total Equity
$251.3M
Cash
$253.8M
LT Debt
$43K
Book Value/Sh
$13.72
Debt/Equity
0.01x
Current Ratio
26.63
Quick Ratio
26.63
Returns & Growth
ROE
-29.5%
ROA
-28.4%
ROIC
-33.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
-3.0%
Price Returns
2W
-4.4%
1M
-17.3%
3M
+12.5%
6M
+24.0%
12M
+37.9%
Technicals
52W High
$37.93
52W Low
$14.71
50d MA
$31.10
200d MA
$25.74
RSI (14)
44.20
ATR (14)
$1.41
Beta
1.33
Avg Volume
202K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$67.50
High
$75.00
Low
$60.00
Median
$67.50
Data updated apr 27, 2026 4:23am
· Source: financialmodelingprep.com